Capricor Therap (CAPR.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec4

Roth MKM analyst maintains buy rating on Capricor Therapeutics

13:27

Dec3

Nippon Shinyaku's CAP-1002 shows positive results in third stage clinical trials for Duchenne Muscular Dystrophy

23:47

Capricor Therapeutics Announces Positive Results for Deramiocel in DMD Phase 3 Trial

12:22

Nov11

Capricor Therap released FY2025 Q3 earnings on November 10 After-Market (EST), actual revenue USD 0 (forecast USD 480K), actual EPS USD -0.5374 (forecast USD -0.5475)

00:00

Capricor Therap released FY2025 9 Months Earnings on November 10 After-Market EST, actual revenue USD 0, actual EPS USD -1.6387

00:00

Nov3

Capricor Therap to Release FY2025 Q3 Earnings on November 10 After-Market EST, Forecast Revenue USD 480 K, EPS USD -0.5475

00:18

Schedules & Filings

Schedules

Filings

Nov10

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -24.57 M, EPS -0.5374

Aug11

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -25.91 M, EPS -0.5668

May13

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -24.39 M, EPS -0.5344

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change